Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Retinal Vein Occlusion Pipeline. Dive into DelveInsight's comprehensive report today! @ Retinal Vein Occlusion Pipeline Outlook
Key Takeaways from the Retinal Vein Occlusion Pipeline Report
In May 2025, Bayer conducted a study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease.
In May 2025, EyeBiotech Ltd announced a Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD).
DelveInsight's Retinal Vein Occlusion Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Retinal Vein Occlusion treatment.
The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others.
Promising Retinal Vein Occlusion Pipeline Therapies such as Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others.
Stay ahead with the most recent pipeline outlook for Retinal Vein Occlusion Treatment. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinal Vein Occlusion Treatment Drugs
Retinal Vein Occlusion Emerging Drugs Profile
KSI-301: Kodiak sciences
The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.
601: Sunshine Guojian Pharmaceutical
601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.
IBE-814: Ripple Therapeutics
IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).
The Retinal Vein Occlusion Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment.
Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion Market
Explore groundbreaking therapies and clinical trials in the Retinal Vein Occlusion Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Retinal Vein Occlusion Drugs
Retinal Vein Occlusion Companies
Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others.
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type
Retinal Vein Occlusion Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Unveil the future of Retinal Vein Occlusion Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Retinal Vein Occlusion Market Drivers and Barriers
Scope of the Retinal Vein Occlusion Pipeline Report
Coverage- Global
Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others.
Retinal Vein Occlusion Pipeline Therapies- Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others.
Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Retinal Vein Occlusion Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Retinal Vein Occlusion Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Retinal Vein Occlusion: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
KSI-301: Kodiak sciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
601: Sunshine Guojian Pharmaceutical
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MHU650: Novartis
Drug profiles in the detailed report…..
Inactive Products
Retinal Vein Occlusion Key Companies
Retinal Vein Occlusion Key Products
Retinal Vein Occlusion- Unmet Needs
Retinal Vein Occlusion- Market Drivers and Barriers
Retinal Vein Occlusion- Future Perspectives and Conclusion
Retinal Vein Occlusion Analyst Views
Retinal Vein Occlusion Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
19 hours ago
- Globe and Mail
3 Best AI Stocks to Buy in August
Key Points A European AI infrastructure company is quietly outgrowing established cloud giants with purpose-built technology and strategic positioning. The productivity software leader is successfully monetizing AI integration across its massive user base, while competitors struggle with adoption. The social media giant's AI investments are already paying dividends in advertising revenue even as it pursues ambitious superintelligence goals. 10 stocks we like better than Nebius Group › Artificial intelligence (AI) is one of the most transformative technologies of our time, driving unprecedented advancements in sectors ranging from healthcare and transportation to communications and beyond. For investors, this creates a landmark opportunity to back the companies at the forefront of this revolution. As we head into August, three companies in particular stand out for their strategic positioning and potential for growth in the AI space. The European dark horse with massive ambitions Nebius Group (NASDAQ: NBIS) is emerging as a serious contender in the AI infrastructure race. The Amsterdam-based company, led by former Yandex founder Arkady Volozh, reported staggering 385% year-over-year revenue growth in Q1 2025, reaching $55.3 million, driven primarily by demand for its AI infrastructure services. The stock has surged 92% year to date as investors begin to take notice. What sets Nebius apart is its vertically integrated approach. Rather than retrofitting general-purpose cloud infrastructure for AI workloads, Nebius builds custom hardware and software specifically for intensive AI training and inference. The company expects to reach $750 million to $1 billion in annual recurring revenue (ARR) by the end of 2025. Backed by 94% low-carbon electricity and a Europe-first strategy, Nebius is positioning itself as a credible long-term alternative to the U.S. hyperscalers, making it one of the most compelling buy-and-hold plays in the AI infrastructure space. The productivity powerhouse monetizing AI at scale Microsoft (NASDAQ: MSFT) stands out as the most pragmatic AI play in tech, with shares up roughly 24% year to date. In fiscal year 2025, the company reported that Azure and other cloud services generated more than $75 billion in revenue, marking a 34% year over year increase. Microsoft also posted $76.4 billion in total revenue for its fiscal fourth quarter, beating analyst expectations and pushing shares to new highs. Microsoft's strength lies in its integration strategy. Rather than launching stand-alone AI tools, the company has embedded Copilot across its core productivity suite, contributing to measurable growth across Microsoft 365 and cloud services. Teams Phone adoption surpassed 20 million users, and Copilot-enabled services now reach more than 100 million. With over a billion users across Office and Windows, Microsoft has unmatched distribution for scaling AI tools globally. The company plans to invest $30 billion this quarter alone in AI-enabled infrastructure, reinforcing its leadership in both profitability and long-term platform dominance. What's the bottom line? While others race to catch up, Microsoft is already cashing in, turning its massive installed base into the most profitable AI deployment machine on the planet. The advertising giant reimagining social with superintelligence Meta Platforms (NASDAQ: META) is taking the most aggressive swing at AI integration, with shares climbing 29% year to date after a blowout Q2. Total revenue hit $47.5 billion, up 22% from the prior year, with advertising contributing $46.6 billion and outperforming expectations. CEO Mark Zuckerberg's push to embed "personal superintelligence" across its platforms is beginning to show measurable traction. Advanced AI tools are powering more precise ad delivery and improved monetization, while the company's $14.3 billion stake in Scale AI signals an intent to anchor the next generation of core models. Daily engagement remains strong, with 3.48 billion people using Meta's apps each day as of June 2025, a 6% year-over-year gain. Meta lifted its full-year capital expenditure forecast to between $66 billion and $72 billion, largely to support AI infrastructure and training. But with profit engines running at full speed and unmatched insight into user behavior, Meta is gearing up to dominate the global attention economy. The AI infrastructure build-out is just beginning These three companies represent distinct strategies in the ongoing AI hyperbuild. Nebius offers pure-play infrastructure exposure with a European edge; Microsoft delivers integrated productivity gains with immediate monetization; and Meta combines massive social scale with leading-edge AI development. For long-term investors, holding all three offers a balanced way to capture the full spectrum of AI-driven value creation. Should you invest $1,000 in Nebius Group right now? Before you buy stock in Nebius Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nebius Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
a day ago
- Globe and Mail
Why Arm Holdings Stock Sank by Over 15% This Week
Key Points The company's second-quarter results displeased many investors. They also inspired some analyst price target cuts. 10 stocks we like better than Arm Holdings › Arm Holdings (NASDAQ: ARM) felt something like an unwanted limb over the past few days, largely because of an earnings report that struck the wrong chord with more than a few investors. Several analyst price target cuts only highlighted this disappointment. Ultimately, according to data compiled by S&P Global Market Intelligence, the specialty tech company's shares plummeted by over 15% this week. Top-line growth, bottom-line slide U.K.-based Arm published its results for the first quarter of its fiscal 2026 on Wednesday. The report showed that the company managed to increase its total revenue by 12% year over year to slightly more than $1.05 billion. That was largely due to a 25% increase in royalty revenue, which landed at $585 million, and despite a 1% slump in licensing revenue to $468 million. Non- GAAP (adjusted) net income traveled in the opposite direction. It fell to $374 million, or $0.35 per share, compared with the year-ago profit of $419 million. With those numbers, Arm met the consensus analyst estimate for profitability, although it missed slightly on revenue -- pundits following the stock were expecting it to earn $1.06 billion. More of a concern for investors was management's guidance for the company's current (second) quarter. Its forecast is for $1.01 billion to $1.11 billion in revenue, which, if achieved, would be down or, at best, essentially flat over the first quarter. Meanwhile, adjusted earnings were forecast at $0.29 to $0.37. Bearish analyst moves Although analyst reactions to the quarter were mixed, enough pundits trimmed their price targets to affect sentiment on the stock. UBS 's Timothy Arcuri, for one, shaved his fair value assessment to $175 per Arm share from his preceding $185. He did, however, maintain his buy recommendation. Lee Simpson of Morgan Stanley acted similarly, reducing the price target to $180 per share from $194 while keeping an overweight (buy, in other words) rating intact. Should you invest $1,000 in Arm Holdings right now? Before you buy stock in Arm Holdings, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arm Holdings wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
